Clinical Trials
24 trialsNCT07615894 2026-05-29
WSK-IM02 in Advanced Solid Tumors With Malignant Effusions (Phase I)
WestVac Biopharma Co., Ltd.
Phase 1 Not yet recruiting
NCT06097962 2026-05-20
Safety and Efficacy of NK510 to Treat NSCLC
Base Therapeutics (Shanghai) Co., Ltd.
Phase EARLY_PHASE1 Recruiting
NCT05543330 2026-05-14
A Phase Ib/II Clinical Trial of M701 in the Treatment of Malignant Pleural Effusions Caused by NSCLC
Wuhan YZY Biopharma Co., Ltd.
Phase 1/2 Recruiting
NCT04914598 2026-01-02
A Phase â…¢ Clinical Study of Combined Cisplatin Versus Placebo Combined With Intracavitary Cisplatin Injection in the Treatment of Malignant Pleural Effusions
Jiangsu Simcere Pharmaceutical Co., Ltd.
Phase 3 Active not recruiting
NCT02649894 2025-12-11
SWIFT
C. R. Bard
Phase NA Completed
NCT02227732 2025-11-26
A Pilot Study Evaluating the Safety and Effectiveness of a New Pleural Catheter for the Medical Management of Symptomatic, Recurrent, Malignant Pleural Effusions
C. R. Bard
Phase NA Completed
NCT06210685 2025-08-11
The ACES Study for Aseptic Pleural Effusion
Pleural Dynamics, Inc.
Phase NA Active not recruiting
NCT06740019 2025-04-04
A Phase Ib Study of JMKX000197 Injection in the Treatment of Malignant Pleural Effusion
Jemincare
Phase 1 Recruiting
NCT06726564 2024-12-10
A Study of MT027 in Patients with Pleural Malignant Tumors
Suzhou Maximum Bio-tech Co., Ltd.
Phase 1 Recruiting
NCT00791154 2024-08-23
SCLC
NantCell, Inc.
Phase 1/2 Terminated
NCT05278975 2024-01-26
Study of RSO-021 in Patients With Malignant Pleural Effusion Due to Advanced/Metastatic Solid Tumors Including Mesothelioma
RS Oncology LLC
Phase 1/2 Unknown
NCT01997190 2023-08-25
MpeTK01
Candel Therapeutics, Inc.
Phase 1 Completed
NCT05923515 2023-06-28
A Phase I Study of JMKX000197 Injection in the Treatment of Malignant Pleural Effusion
Jemincare
Phase 1 Unknown
NCT00858364 2022-11-30
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Amgen
Phase 3 Terminated
NCT04123886 2022-05-06
A Phase I Study Evaluating SCB-313(Recombinant Human TRAIL-Trimer Fusion Protein) for the Treatment of Malignant Pleural Effusion
Sichuan Clover Biopharmaceuticals, Inc.
Phase 1 Completed
NCT03869697 2022-02-02
Study With SCB-313 (Recombinant Human TRAIL-Trimer Fusion Protein) for Treatment of Malignant Pleural Effusions
Clover Biopharmaceuticals, Ltd
Phase 1 Completed
NCT04254445 2020-02-18
Use of Guidance Videos to Increase Engagement and Decrease Anxiety in Patients Undergoing Pleural Tap
GistMed Ltd.
Phase NA Unknown
NCT03736122 2018-11-08
A Study of Syngenon (BSG-001) for Inhalation in Subjects With Malignant Pleural Effusion and/or Malignant Ascites
BioSyngen Pte Ltd
Phase 1/2 Unknown
NCT00005645 2018-09-18
ILX-295501 in Treating Patients With Stage III or Stage IV Ovarian Cancer That Has Not Responded to Previous Treatment
Sanofi
Phase 2 Withdrawn
NCT02429726 2015-04-29
Recombinant Adenoviral Human p53 Gene in Treatment of Malignant Pleural Effusion
Shenzhen SiBiono GeneTech Co.,Ltd
Phase 2 Unknown
NCT01327235 2014-08-01
Endostar and/or Cisplatin for Treatment of Malignant Pleural Effusion or Ascites
Jiangsu Simcere Pharmaceutical Co., Ltd.
Phase 2 Completed
NCT02191540 2014-07-23
Efficacy and Safety Study of Abnoba Viscum F 20mg in Malignant Pleural Effusion Patients
Abnoba Korea
Phase 3 Completed
NCT00343291 2011-06-07
A Study of Cetuximab and Bevacizumab in Combination With Paclitaxel and Carboplatin in Stage IIIb/IV NSCLC
Eli Lilly and Company
Phase 2 Completed
NCT00099541 2009-11-23
Non-small Cell Lung Cancer Registry
Novartis
Phase 4 Completed